MissMiner Posted - 2 hours ago

$XENE bought

TipRanks Posted - 5 hours ago

JPMorgan Selects These 2 Stocks as Must-Haves for 2025 https://www.tipranks.com/news/article/jpmorgan-selects-these-2-stocks-as-must-haves-for-2025 $HASI $XENE

Rileyr15R Posted - 1 day ago

$XENE $PTCT LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

zmanx Posted - 2 days ago

$XENE still sitting patiently here… next year should see some data readout.

Amudlino Posted - 5 days ago

😏🚀 MYNZ We know the date of the reverse split (RS) if there will be one, but possibly a Nasdaq extension will be granted. Last time it traded, 50 million and 19 million heavy shorts attacked. Now, it has huge credibility after the TMO partnership and the meeting. The company will decide by November 25th whether or not to do an RS based on Nasdaq's response. Anyway, after the RS, I'm not worried about what happens next. A $210 billion partner TMO signing a deal with a penny stock has never happened before. I will be loading heavy on Monday. This will go to the moon like the DRUG stock recently did. The price target (PT) is $50. The squeeze will be parabolic. $HCM $XENE

DonCorleone77 Posted - 1 week ago

$XENE Xenon Pharmaceuticals reports Q3 EPS (81c), consensus (81c) "Xenon's leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple indications that is backed by long-term efficacy and safety data with over 600-patient years of exposure in patients living with epilepsy. Importantly, we generated highly compelling double-blind efficacy data that we believe demonstrates the best placebo-adjusted results in focal onset seizure patients, and excitement around azetukalner is building as we continue to progress toward the X-TOLE2 topline data readout expected in the second half of 2025," stated Ian Mortimer, President and Chief Executive Officer of Xenon. "Within the X-TOLE open-label extension study, we are seeing patients - some who have been on azetukalner for more than 5 years - experience the long-term benefits of seizure freedom and improved quality of life, as well as a favorable tolerability profile and we are excited to present new 36-month data at the American Epilepsy Society annual meeting next month."

Estimize Posted - 1 week ago

$XENE reports after the close, Estimize Consensus +0.02 EPS and +0 Revs compared to WS http://www.estimize.com/xene/fq3-2024?utm_content=pr

ChessGM Posted - 1 week ago

$XENE Heads up alert! Only one day until Upcoming earnings on Tuesday, 11/12/2024 for $XENE Consensus Signal: Neutral (5.0) Xenon Pharmaceuticals Inc. (XENE) continues to navigate a complex landscape in the biopharmaceutical sector, particularly in the realms of epilepsy and depression therapies. The company's recent announcement regarding its upcoming Q3 2024 financial results, coupled with robust highlights from its Q2 earnings call, indicates a stable financial position. Key metrics such as a P/E ratio that remains competitive within the industry and a projected EPS growth that aligns with sector benchmarks suggest potential for sustained investor interest. Moreover, revenue forecasts appear optimistic, largely bolstered by advancements in its therapeutic pipeline and strategic positioning in the neuroscience domain. When compared to industry peers, Xenon shows promise, particularly in areas where competitors have faced challenges, such as over-reliance on single product sales, as seen with Intra-Cellular's Caplyta. This positions XENE as a potentially attractive investment in the neuro-focused biopharmaceutical space. In terms of upcoming earnings reports, Xenon is set to release its Q3 2024 financial results on November 12, 2024. Analysts are cautiously optimistic, anticipating continued growth driven by strategic advances in its drug development efforts. Historical performance indicates that Xenon has successfully met or exceeded earnings expectations in past quarters, which could set a positive tone for the upcoming report. Current analyst consensus estimates suggest steady revenue growth, and any positive surprises could significantly impact stock performance, especially as the market reacts to developments in their pipeline and overall market conditions. Investors should keep an eye on the conference call following the earnings release, as insights into strategic initiatives and guidance for future quarters will likely influence sentiment and stock price movements. - Funds were net buyers of $XENE during the previous reporting quarter. - Here are some of the funds with a sizable holdings (as of Q3 of 2024) for $XENE: * Avoro Capital Advisors LLC $221MM. New position. CGMFundRank: 83%, Fund Website: avorocapital.com * Paradigm Biocap $80MM. New position. CGMFundRank: 55% * Adage Capital P $72MM. New position. CGMFundRank: 88%, Fund Website: www.adagecapital.com * First Light Asset Management LLC $51MM. New position. CGMFundRank: 59%, Fund Website: www.firstlightam.com * Baker Brothers Advisors LP $39MM. New position. CGMFundRank: 75%, Fund Website: www.edgr.io - Last 10 days performance: 8% - Last 30 days performance: 9% - Last 90 days performance: 16% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.

BioTrade2 Posted - 2 weeks ago

$XENE stuck in this range for a year (38-50). Can we now breakout!?!?

Estimize Posted - 10/28/24

$XENE estimates distribution - here’s what 3 Estimize analysts are expecting $XENE to report for Q3 [Reporting 11/05 AMC] http://www.estimi

Doozio Posted - 1 month ago

$XENE 2mro is $wen a 🧠👀 becomes da FUTUre of 🧠⏰ NOW during 🧠⏰♾️. Obviously

themacromindset Posted - 1 month ago

$XENE Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference $XENE

Telefon Posted - 2 months ago

$ELTP Elite Pharmaceuticals - Drugs Awaiting Launch and Total Market Value Methotrexate ($63.4M): Recently FDA approved, launching this quarter. Generic APAP with Codeine ($45M): Brand name Tylenol with Codeine, launching 6-8 weeks after Methotrexate. Oxy APAP ($500M): Generic Percocet, launching 6-8 weeks after APAP with Codeine. Hydro APAP ($477M): Generic Norco, launching after Oxy APAP. Methadone ($30M): Launching after Hydro APAP. Generic Vyvanse ($5.1B): Pending FDA approval, will take priority upon approval. Total Potential Market Value: $6.215 Billion $XENE $RYTM $MDGL $VKTX

StockInvest_us Posted - 2 months ago

Signal alert: $XENE - Oversold Trend Short (Undervalued) https://stockinvest.us/l/OwQ2g67Dgp

Quantumup Posted - 08/26/24

BofA🏁 $BHVN Buy/$52, says "Buy Biohaven for upside potential tied to degrader and neuropsych clinical programs." "Fast-follower" strat🎯s attractive mkts: 1300/1310 offer pot for $2B in peak sales by 2040e; '7000 can be BiC=most advd program, w/ multi-Billion peak rev pot: $xene

StockInvest_us Posted - 3 months ago

Signal alert: $XENE - Possible Runner https://stockinvest.us/l/BXhGEvN0fz

AnaChart Posted - 3 months ago

$XENE https://anachart.com/wp-content/uploads/ana_temp/1723456871_soc-img.jpg

Thestocktraderhubzee Posted - 3 months ago

$XENE Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Estimize Posted - 3 months ago

$XENE misses the Estimize EPS Consensus by 7c and the Estimize Revenue Consensus by $0.01M. Reports FQ2 earnings of -75c EPS and $0M Revs http://www.estimize.com/xene/fq2-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

epsguid Posted - 3 months ago

$XENE reported a loss of $0.75, consensus was ($0.72) via @eWhispers #epsmiss http://eps.sh/d/xene

DonCorleone77 Posted - 3 months ago

$XENE Xenon Pharmaceuticals reports Q2 EPS (75c), consensus (70c) Reports Cash and cash equivalents and marketable securities were $850.6M as of June 30, compared to $930.9 M as of December 31, 2023. Based on current operating plans, including the completion of the azetukalner Phase 3 epilepsy studies and fully supporting late-stage clinical development of azetukalner in MDD, Xenon anticipates having sufficient cash to fund operations into 2027. As of June 30, 2024, there were 75,667,550 common shares and 2,173,081 pre-funded warrants outstanding. "We are proud to have the only Kv7 potassium channel opener in development with Phase 2b efficacy and long-term safety data in epilepsy patients. Today people living with epilepsy are still struggling to control seizures despite current medications, and we believe the compelling profile of azetukalner has the potential to be paradigm shifting in the future treatment of epilepsy," stated Ian Mortimer, President and Chief Executive Officer of Xenon. "We continue to progress our epilepsy program with plans to deliver X-TOLE2 topline data in the second half of 2025, in support of our expected NDA submission." Mr. Mortimer continued, "Beyond azetukalner, we continue to build upon our Kv7 leadership with a broad portfolio of diverse chemistries to support our 'pipeline in a mechanism' approach. In parallel, we are advancing promising Nav1.7 candidates towards early human proof-of-concept in pain. We believe that the advancements in our azetukalner development programs in epilepsy and MDD, with our maturing pre-clinical pipeline, position Xenon with one of the most exciting CNS portfolios that exists today."

Stock_Titan Posted - 3 months ago

$XENE Xenon Reports Q2 2024 Financial Results and Business Update https://www.stocktitan.net/news/XENE/xenon-reports-q2-2024-financial-results-and-business-0z9z90q3kc72.html

Estimize Posted - 3 months ago

$XENE reports after the close, Estimize Consensus +0.02 EPS and +0.01M Revs compared to WS http://www.estimize.com/xene/fq2-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

NVDAMillionaire Posted - 3 months ago

$XENE Xenon Pharmaceuticals Inc. (XENE): A Promising Neuroscience-Focused Biopharmaceutical Company http://beyondspx.com/2024/08/01/xenon-pharmaceuticals-inc-xene-a-promising-neuroscience-focused-biopharmaceutical-company/

Stock_Titan Posted - 3 months ago

$XENE Xenon to Report Q2 2024 Financial Results on August 8, 2024 https://www.stocktitan.net/news/XENE/xenon-to-report-q2-2024-financial-results-on-august-8-7o9jetl2mnd8.html

StockInvest_us Posted - 4 months ago

Signal alert: $XENE - Double Bottom https://stockinvest.us/l/DCT0FttmAi

TickerDD_com Posted - 5 months ago

From 5/20/2024, looking back across 21 Month-Ends for XENE, Percentage Change of Average Monthly Price had More Negatives (55%) while Percentage Change of Average Monthly Volume had All Positives (100%) $XENE #XENE #XENEStock #TickerDD https://www.youtube.com/watch?v=fVBt0EPbZeU

Quantumup Posted - 5 months ago

RBC Capital reiterated $XENE Outperform/$55 RBC came out w/ reaffirmed confidence the first '1101 P3 readout will look favorable/success can=$1.1B peak out-year U.S. epilepsy sales opp, after neurologists survey: MDs=enthusiasm4profile, high desire2 Rx across all lines/they see good PoS: $bhvn

cubie Posted - 5 months ago

$SMMT apparently u never seen bios go up on their offerings $xene $imvt $eypt $kros just to name a few, lord 🙄

DonCorleone77 Posted - 05/28/24

$XENE Xenon Pharmaceuticals presents data from Phase 2 X-Nova trial Xenon Pharmaceuticals announced data presentations highlighting azetukalner, XEN1101, clinical data in major depressive disorder, MDD, at the American Society of Clinical Psychopharmacology, ASCP, 2024 Annual Meeting in Miami, FL. Summary of Efficacy Data: The primary endpoint of the study was a change in the Montgomery-Asberg Depression Rating Scale, or MADRS, at week 6. The mean reduction was 13.90 in the placebo group, 15.61 in the 10 mg group and 16.94 in the 20 mg group. A clear dose response and a clinically meaningful, but not statistically significant. At week 1, the mean reduction in MADRS score from baseline was significantly different between placebo and azetukalner 20 mg groups, demonstrating early onset of efficacy. The mean reduction in the Hamilton Depression Rating Scale, or HAM-D17, score from baseline to week 6 was significantly different between placebo and azetukalner 20 mg groups. The mean reduction in the Snaith-Hamilton Pleasure Scale, or SHAPS, score from baseline to week 6 was significantly different between placebo and azetukalner 20 mg groups. There were no statistically significant differences in change from baseline BAI total scores to week 6 between placebo and azetukalner groups. Statistical significance was achieved in reporting of at least minimally improved symptoms of depression as assessed by physicians using the Clinical Global Impression of Improvement in the azetukalner 20 mg group compared to placebo. Summary of Safety and Tolerability Data: Azetukalner was well tolerated with a low incidence of treatment-emergent adverse events, and no serious TEAEs were reported in either dose group.